|
¸¶ÀϽºÅæ¼Ä¡ |
Market Access(¾à°¡´ã´çÀÚ)/±¹³»majorÁ¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
1³â¡è |
ä¿ë½Ã |
12.03 |
|
|
JYpartners |
[[µ¶ÀÏ°è Åõ¼® Àü¹®±â¾÷]]PV manager ½Å±Ôä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
12.03 |
|
|
´õÀ⽺ |
¾à»çÀڰݺ¸À¯ÇÑ ÀÓ¿ø±Þ °øÀåÀå(Á¦¾à,°Ç°½ÄÇ°)ä¿ë
ÃæºÏ Á¦Ãµ½Ã | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
14³â¡è |
ä¿ë½Ã |
12.01 |
|
|
(ÁÖ)¸®¿ÂÆÄÆ®³Ê½º |
Country Head, Manager, Sr./Jr. cra ±Û·Î¹ú Pharm/cro(ÀçÅÃ
¼¿ï °³²±¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
12.01 |
|
|
JYpartners |
[[µ¶ÀÏ°è Åõ¼® Àü¹®±â¾÷]] Sales&Marketing ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
2³â¡è |
ä¿ë½Ã |
11.02 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Medical Advisor/±¹³»À¯¸íÁ¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
˂ȍ |
2³â¡è |
ä¿ë½Ã |
11.02 |
|
|
JYpartners |
[[µ¶ÀÏ°è Åõ¼® Àü¹®±â¾÷]]PV manager ½Å±Ôä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
3³â¡è |
ä¿ë½Ã |
11.02 |
|
|
¹Ý¼®½áÄ¡(ÁÖ) |
¾à»ç ¹× Á¦Á¦¿¬±¸ÆÀÀå ¸ðÁý
Ãæ³² ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
3³â¡è |
»ó½Ãä¿ë |
10.03 |
|
|
(ÁÖ)ºê·£µå¹Ì |
´ë±â¾÷ Ç°Áú°ü¸® ¾à»ç ´ëÀü±Ù¹«
´ëÀü ´ë´ö±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
10.03 |
|
|
(ÁÖ)ºê·£µå¹Ì |
±×·ì °è¿»ç ÀǾà Ç°Áú°ü¸® ¾à»ç
´ëÀü ÀüÁö¿ª, ¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
09.22 |
|
|
(ÁÖ)ÇÇÇÃÄɾî½áÄ¡ |
Ç°Áú°ü¸® ¾à»ç QA - ÃÖ°í ´ë±â¾÷
´ëÀü ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
5³â¡è |
ä¿ë½Ã |
08.26 |
|
|
(ÁÖ)ÇÁ¶óÀ̸Ӹ®¿¡ÀÌÄ¡¾Ë |
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
3³â¡è |
ä¿ë½Ã |
08.26 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
MSL(Oncology)/À¯¸í¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
1³â¡è |
ä¿ë½Ã |
08.03 |
|
|
(ÁÖ)ÇÇÇÃÄɾî½áÄ¡ |
Pharmacist -¿Ü±¹°èÁ¦¾à»ç
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
6³â¡è |
ä¿ë½Ã |
07.13 |
|
|
ÁÖ½Äȸ»ç ÀÎÅÚ¸®Àü½ºÄÚ¸®¾Æ |
[¿Ü±¹°èÁ¦¾à»ç] CRA
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
5³â¡è |
ä¿ë½Ã |
07.07 |
|